FilingSEC EDGAR8-K
Aprea Therapeutics Reports Q3 Results and Provides Clinical Pipeline Update
· SEC accepted
StagePhase 1
Filing content
Aprea Therapeutics reported its third-quarter 2026 financial results, provided updates on its APR-1051 clinical trial, and stated it has sufficient cash runway into the first quarter of 2028.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…